Anna Martling

Anna Martling

Professor/Överläkare
E-postadress: anna.martling@ki.se
Telefon: +46852482725
Besöksadress: Elite Hotell, plan 2, Eugeniavägen 6, 17176 Stockholm
Postadress: K1 Molekylär medicin och kirurgi, K1 MMK Kolorektalkirurgi, 171 76 Stockholm
Del av:

Om mig

  • Anna Martling är professor i kirurgi vid Karolinska Institutet i Stockholm. Hon disputerade 2003 med en avhandling om ändtarmscancer, blev specialist i kirurgi 2004 och docent 2009. År 2014 utnämndes hon till professor i kirurgi.


    Professor Martling har haft flera betydande akademiska uppdrag vid Karolinska Institutet. Under perioden 2015–2018 var hon lärarrepresentant i Styrelsen för forskning. Mellan 2019 och 2023 var hon dekan för Campus Nord. Inom ramen för detta uppdrag hade hon ett övergripande ansvar för att koordinera och driva implementeringen av precisionsmedicin i hälso- och sjukvården inom Region Stockholm under åren 2020–2024. Under 2024 verkade hon som Scientific Director för Life Science vid Karolinska Institutet i Stockholm.

    Sedan 2008 leder hon en forskargrupp och ansvarar för forskningsområdet kolorektalkirurgi, med särskilt fokus på kliniska, translationella och epidemiologiska studier av kolorektal cancer. Forskningsgruppen har haft ett särskilt intresse för prediktiva och prognostiska biomarkörer, behandling med acetylsalicylsyra, strålbehandling, optimal tidpunkt för kirurgi samt utveckling av nya kirurgiska tekniker. Professor Martling har framgångsrikt integrerat forskningen i den kliniska verksamheten och skapat en unik, kreativ och akademisk miljö som främjar högkvalitativ klinisk forskning.

    Hennes forskning har uppmärksammats med flera prestigefyllda utmärkelser. År 2013 tilldelades hon Svensk Kirurgisk Förenings Stora Forskningspris och 2021 utsågs hon till Årets cancerforskare av Cancerfonden.

    Professor Martling är internationellt erkänd som en ledande expert inom sitt område och är en frekvent inbjuden föreläsare såväl nationellt som internationellt. Hon är hedersledamot (Honorary Fellow) vid Royal College of Surgeons of England (FRCS), American College of Surgeons (FACS), American Society of Colon and Rectal Surgeons (FASCRS) samt European Society of Coloproctology (FESCP).

    Hon är även ordförande för Swedish Colorectal Cancer Study Group, ett nationellt forskningsnätverk inom kolorektal cancer. Under perioden 2015–2018 var hon ordförande för programkommittén inom European Society of Coloproctology (ESCP) och ansvarade för det vetenskapliga programmet vid sällskapets årliga kongress.

    Professor Martlings forskning finansieras av Vetenskapsrådet, Cancerfonden, Radiumhemmets forskningsfonder, Karolinska Institutet och Region Stockholm. År 2014 mottog hon Vetenskapsrådets då största anslag för klinisk behandlingsforskning, om 25 miljoner kronor.



    Angelägna frågor
    Karolinska Institutet (KI) behöver gemensamt utveckla en stimulerande och forskningsstödjande miljö som möjliggör världsledande grundvetenskaplig, translationell och klinisk forskning. Genom att integrera dessa områden kan vi skapa ny kunskap om livet och bidra till att förbättra människors hälsa.

    En central del i detta arbete är utvecklingen och implementeringen av precisionsmedicin. Genom ett fördjupat samarbete mellan KI, SciLifeLab, Karolinska Universitetssjukhuset och Region Stockholm kan nya medicinska rön och teknologier snabbare omsättas i vården, vilket möjliggör mer träffsäkra och individualiserade diagnostiska metoder och behandlingar i internationell framkant. En avgörande förutsättning är att etablera robusta strukturer för lagring, bearbetning, integrering och analys av stora och komplexa datamängder. Detta är centralt både för utvecklingen av precisionsmedicin och för att möjliggöra sekundäranvändning av hälsodata i forskning. KI bör här ta en ledande roll inom datahantering, artificiell intelligens och avancerade analysmetoder för att driva nästa generations medicinska genombrott.

    Samtidigt står KI inför både utmaningar och möjligheter till följd av de pågående förändringarna i sjukvårdsstrukturen inom Region Stockholm. Det är därför avgörande att KI är en aktiv och strategisk part i denna utveckling och tar tillvara möjligheten att forma framtidens forsknings- och utbildningsmiljöer.

    Avgörande för KIs fortsatta utveckling är att etablera en fullt integrerad kunskapsmiljö där akademi och hälso- och sjukvård tillsammans fungerar som en drivkraft för innovation. Detta kräver en ytterligare stärkt integration mellan olika forskningsdiscipliner, samtidigt som vi öppnar upp för nya kompetenser och samarbeten över fakultetsgränser.



    Akademiska priser och utmärkelser

    2023 Honorary Fellow of European Society of Coloproctology (FESCP)

    2023 Honorary Fellow of American College of Surgeons (FACS)

    2022 Honorary Fellow of Royal College of Surgeons of England (FRCS)

    2021 Årets Cancerforskare, Cancerfonden

    2020 Honorary Fellowship of American Society of Colon and Rectal Surgeons (FASCRC)

    2019 Tarmcancerpriset, ILCO

    2019 Med dr Axel Hirsch Pris, Karolinska Institutet 2018 Hilda och Alfred Erikssons pris, Kungliga Vetenskaps Akademin

    2017 Marc-Claude Marti Lecture, Villars, Schweiz

    2016 Årets Lennanderföreläsare, Svenska Läkaresällskapet

    2015 The Edward Wilson Lecture, Sydney, Australia

    2013 Svensk Kirurgisk Förenings Stora Forskarpris

Forskningsbeskrivning

Utvalda publikationer

Artiklar

Alla övriga publikationer

  • Study protocol: BMJ OPEN. 2025;15(11):e095376
    Agache A; Deding U; Kaalby L; Kobaek-Larsen M; Al-Najami I; Ostergaard Hansen L; Stryhn C; Wilde D; Forsberg A; Backman A-S; Bates T; de Lange T; Martling A; Baatrup G
  • Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2025;393(21):2173
    Martling A; Myrberg IH; Lindberg J
  • Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. 2025;241(5):S78
    Martling A
  • Corrigendum: BMC CANCER. 2025;25(1):929
    Ljunggren M; Dietrich CE; Rosander E; Palmer G; Glimelius B; Martling A; Nordenvall C
  • Conference publication: RADIOTHERAPY AND ONCOLOGY. 2025;206:S1170-S1173
    Marijnen CAM; Sebag-Montefiore D; Homer V; Gates S; Al-Najami I; Angenete E; Appelt A; Baatrup G; Beets G; Burger JWA; Spindler K-LG; Geh I; Gilbert A; Haustermans K; Holman F; Korsgen S; Lind P; Martling A; Peters F; Teo M; West N; Wolthuis A; de Wilt JWH; Bach SP
  • Study protocol: BMJ OPEN. 2025;15(4):e100356
    Nilsson PJ; Folkesson J; Marsk R; Radu C; Stratulat I; Blomqvist L; Martling A; Valdman A
  • Letter: BJS-BRITISH JOURNAL OF SURGERY. 2024;111(9):znae241
    Valdman A; Marsk R; Karimi M; Asklid D; Brattstrom D; Ostling Palme J; Martling A; Nilsson PJ
  • Review: CANCERS. 2024;16(8):1539
    Temmink SJD; Peeters KCMJ; Nilsson PJ; Martling A; van de Velde CJH
  • Corrigendum: EUROPEAN JOURNAL OF CANCER. 2024;201:113940
    Osterman E; Syriopoulou E; Martling A; Andersson; Nordenvall C
  • Review: BJS-BRITISH JOURNAL OF SURGERY. 2024;111(3):znae042
    Aalbers AGJ; Aziz AN; Abraham-Nordling M; Akiyoshi T; Alahmadi R; Alberda W; Albert M; Andric M; Angeles M; Antoniou A; Armitage J; Auer R; Austin KK; Aytac E; Baker RP; Bali M; Baransi S; Bebington B; Bedford M; Bednarski BK; Beets GL; Berg PL; Bergzoll C; Biondo S; Boyle K; Bordeianou L; Brecelj E; Bremers AB; Brunner M; Bui A; Burgess A; Burger JWA; Campain N; Carvalhal S; Castro L; Ceelen W; Chan KKL; Chew MH; Chok AK; Chong P; Christensen HK; Clouston H; Collins D; Colquhoun AJ; Constantinides J; Corr A; Coscia M; Cosimelli M; Cotsoglou C; Damjanovic L; Davies M; Davies RJ; Delaney CP; de Wilt JHW; Deutsch C; Dietz D; Domingo S; Dozois EJ; Duff M; Egger E; Enrique-Navascues JM; Espin-Basany E; Eyjolfsdottir B; Fahy M; Fearnhead NS; Fichtner-Feigl S; Fleming F; Flor B; Foskett K; Funder J; Garcia-Granero E; Garcia-Sabrido JL; Gargiulo M; Gava VG; Gentilini L; ML G; George V; Georgiou P; Ghosh A; Ghouti L; Giner F; Ginther N; Glover T; Golda T; Gomez CM; Harris C; Hagemans JAW; Hanchanale V; Harji DP; Helbren C; Helewa RM; Hellawell G; Heriot AG; Hochman D; Hohenberger W; Holm T; Holmstrom A; Hompes R; Hornung B; Hurton S; Hyun E; Ito M; Jenkins JT; Jourand K; Kaffenberger S; Kapur S; Kanemitsu Y; Kaufman M; Kelley SR; DS K; Kersting S; Ketelaers SHJ; Khan MS; Khaw J; Kim H; Kim HJ; Kiran R; Koh CE; Kok NFM; Kontovounisios C; Kose F; Koutra M; Kraft M; Kristensen HO; Kumar S; Lago V; Lakkis Z; Lampe B; Larsen SG; Larson DW; Law WL; Laurberg S; Lee PJ; Limbert M; Loria A; Lynch AC; Mackintosh M; Mantyh C; Mathis KL; Margues CFS; Martinez A; Martling A; Meijerink WJHJ; Merchea A; Merkel S; Mehta AM; McArthur DR; McCormick JJ; McGrath JS; McPhee A; Maciel J; Malde S; Manfredelli S; Mikalauskas S; Modest D; Morton JR; Mullaney TG; Navarro AS; Neto JWM; Nguyen B; Nielsen MB; Nieuwenhuijzen GAP; Nilsson PJ; Nordkamp S; O'Dwyer ST; Paarnio K; Pappou E; Park J; Patsouras D; Peacock O; Pfeffer F; Piqeur F; Pinson J; Poggioli G; Proud D; Quinn M; Oliver A; Radwan RW; Rajendran N; Rao C; Rasheed S; Rasmussen PC; Rausa E; Regenbogen SE; Reims HM; Renehan A; Rintala J; Rocha R; Rochester M; Rohila J; Rottoli M; Roxburgh C; Rutten HJT; Safar B; Sagar PM; Sahai A; Schizas AMP; Schwarzkopf E; Scripcariu D; Scripcariu V; Seifert G; Selvasekar C; Shaban M; Shaikh I; Shida D; Simpson A; Skeie-Jensen T; Smart P; Smith JJ; Solbakken AM; Solomon MJ; Sorensen MM; Spasojevic M; Steffens D; Stocchi L; Stylianides NA; Swartling T; Sumrien H; Swartking T; Takala H; Tan EJ; Taylor D; Tejedor P; Tekin A; Tekkis PP; Thaysen HV; Thurairaja R; Toh EL; Tsarkov P; Tolenaar J; Tsukada Y; Tsukamoto S; Tuech JJ; Turner G; Turner WH; Tuynman JB; Valente M; van Rees J; van Zoggel D; Vasquez-Jimenez W; Verhoef C; Vierimaa M; Vizzielli G; Voogt ELK; Uehara K; Wakeman C; Warrier S; Wasmuth HH; Weiser MR; Westney OL; Wheeler JMD; Wild J; Wilson M; Yano H; Yip B; Yip J; Yoo RN; Zappa MA
  • Study protocol: BMJ OPEN. 2024;14(2):e076538
    West CT; West MA; Drami I; Denys A; Glyn T; Sutton PA; Tiernan J; Behrenbruch C; Guerra G; Waters PS; Woodward N; Applin S; Charles SJ; Rose SA; Pape E; van Ramshorst GH; Mirnezami AH; Aalbers AGJ; Abdul AN; Abecasis N; Abraham-Nordling M; Akiyoshi T; Alahmadi R; Alberda W; Albert M; Andric M; Angeles M; Angenete E; Antoniou A; Armitage J; Auer R; Austin KK; Aytac E; Aziz O; Bacalbasa N; Baker RP; Bali M; Baransi S; Baseckas G; Bebington B; Bedford M; Bednarski BK; Beets GL; Berg PL; Bergzoll C; Beynon J; Biondo S; Boyle K; Bordeianou L; Brecelj E; Bremers AB; Brown K; Brunner M; Buchwald P; Bui A; Burgess A; Burger JWA; Burling D; Burns E; Campain N; Carvalhal S; Castro L; Caycedo-Marulanda A; Ceelen W; Chan KKL; Chang GJ; Chew MH; Chok AK; Chong P; Christensen HK; Clouston H; Collins D; Colquhoun AJ; Constantinides J; Corr A; Coscia M; Cosimelli M; Cotsoglou C; Coyne PE; Croner RS; Damjanovic L; Daniels IR; Davies M; Davies RJ; Delaney CP; de Wilt JHW; Denost QD; Deutsch C; Dietz D; Domingo S; Dozois EJ; Drozdov E; Duff M; Egger E; Eglinton T; Enrique-Navascues JM; Espin-Basany E; Evans MD; Eyjolfsdottir B; Fahy M; Fearnhead NS; Fichtner-Feigl S; Flatmark K; Fleming F; Flor B; Folkesson J; Foskett K; Frizelle FA; Funder J; Gallego MA; Garcia-Granero E; Garcia-Sabrido JL; Gargiulo M; Gava VG; Gentilini L; George ML; George V; Georgiou P; Ghosh A; Ghouti L; Gil-Moreno A; Giner F; Ginther N; Glover T; Goffredo P; Golda T; Gomez CM; Griffiths B; Gwenael F; Harris C; Harris DA; Hagemans JAW; Hanchanale V; Harji DP; Helbren C; Helewa RM; Hellawell G; Heriot AG; Hochman D; Hohenberger W; Holm T; Holmstrom A; Hompes R; Hornung B; Hurton S; Hyun E; Ito M; Iversen LH; Jenkins JT; Jourand K; Kaffenberger S; Kandaswamy GV; Kapur S; Kanemitsu Y; Kaufman M; Kazi M; Kelley SR; Keller DS; Kelly ME; Kersting S; Ketelaers SHJ; Khan MS; Khaw J; Kim H; Kim HJ; Kiran R; Koh CE; Kok NFM; Kokelaar R; Kontovounisios C; Kose F; Koutra M; Kraft M; Kristensen HO; Kumar S; Kusters M; Lago V; Lakkis Z; Lampe B; Langheinrich MC; Larach T; Larsen SG; Larson DW; Law WL; Laurberg S; Lee PJ; Limbert M; Loria A; Lydrup ML; Lyons A; Lynch AC; Mackintosh M; Mann C; Mantyh C; Mathis KL; Margues CFS; Martinez A; Martling A; Meijerink WJHJ; Merchea A; Merkel S; Mehta AM; McArthur DR; McCormick JJ; McDermott FD; McGrath JS; McPhee A; Maciel J; Malde S; Manfredelli S; Mikalauskas S; Modest D; Monson JRT; Morton JR; Mullaney TG; Navarro AS; Neeff H; Negoi I; Neto JWM; Nguyen B; Nielsen MB; Nieuwenhuijzen GAP; Nilsson PJ; Nordkamp S; O'Dwyer ST; Paarnio K; Palmer G; Pappou E; Park J; Patsouras D; Peacock O; Pellino G; Peterson AC; Pfeffer F; Piqeur F; Pinson J; Poggioli G; Proud D; Quinn M; Oliver A; Quyn A; Radwan RW; Rajendran N; Rao C; Rasheed S; Rasmussen PC; Rausa E; Regenbogen SE; Reims HM; Renehan A; Rintala J; Rocha R; Rochester M; Rohila J; Rothbarth J; Rottoli M; Roxburgh C; Rutten HJT; Safar B; Sagar PM; Sahai A; Saklani A; Sammour T; Sayyed R; Schizas AMP; Schwarzkopf E; Scripcariu D; Scripcariu V; Seifert G; Selvasekar C; Shaban M; Shaikh I; Shida D; Simpson A; Skeie-Jensen T; Smart NJ; Smart P; Smith JJ; Smith T; Solbakken AM; Solomon MJ; Sorensen MM; Sorrentino L; Spasojevic M; Steele SR; Steffens D; Stitzenberg K; Stocchi L; Stylianides NA; Swartling T; Sumrien H; Swartking T; Takala H; Tan EJ; Taylor C; Taylor D; Tejedor P; Tekin A; Tekkis PP; Teras J; Thanapal MR; Thaysen HV; Thorgersen E; Thurairaja R; Toh EL; Tsarkov P; Tolenaar J; Tsukada Y; Tsukamoto S; Tuech JJ; Turner G; Turner WH; Tuynman JB; Valente M; van Rees J; van Zoggel D; Vasquez-Jimenez W; Verhoef C; Vierimaa M; Vizzielli G; Voogt ELK; Uehara K; Wakeman C; Warrier S; Wasmuth HH; Weber K; Weiser MR; Westney OL; Wheeler JMD; Wild J; Wilson M; Wolthuis A; Yano H; Yip B; Yip J; Yoo RN; Zappa MA; Winter DC
  • Conference publication: JOURNAL OF CROHNS & COLITIS. 2024;18:I1954
    Lundqvist E; Westerberg K; Dietrich C; Martling A; Myrelid P; Nordenvall C
  • Editorial: BJS-BRITISH JOURNAL OF SURGERY. 2023;110(12):1730-1731
    West CT; West MA; Mirnezami AH; Drami I; Denys A; Glyn T; Sutton PA; Tiernan J; Behrenbruch C; Guerra G; Waters PS; Woodward N; Applin S; Charles SJ; Rose SA; Pape E; van Ramshorst GH; Aalbers AGJ; Abdul AN; Abecasis N; Abraham-Nordling M; Akiyoshi T; Alahmadi R; Alberda W; Albert M; Andric M; Angeles M; Angenete E; Antoniou A; Armitage J; Auer R; Austin KK; Aytac E; Aziz O; Bacalbasa N; Baker RP; Bali M; Baransi S; Baseckas G; Bebington B; Bedford M; Bednarski BK; Beets GL; Berg PL; Bergzoll C; Biondo S; Boyle K; Bordeianou L; Brecelj E; Bremers AB; Brown K; Brunner M; Buchwald P; Bui A; Burgess A; Burger JWA; Burling D; Burns E; Campain N; Carvalhal S; Castro L; Caycedo-Marulanda A; Ceelen W; Chan KKL; Chang GJ; Chew MH; Chok AK; Chong P; Christensen HK; Clouston H; Collins D; Colquhoun AJ; Constantinides J; Corr A; Coscia M; Cosimelli M; Cotsoglou C; Coyne PE; Croner RS; Damjanovic L; Daniels IR; Davies M; Davies RJ; Delaney CP; de Wilt JHW; Denost QD; Deutsch C; Dietz D; Domingo S; Dozois EJ; Drozdov E; Duff M; Egger E; Eglinton T; Enrique-Navascues JM; Espin-Basany E; Evans MD; Eyjolfsdottir B; Fahy M; Fearnhead NS; Fichtner-Feigl S; Flatmark K; Fleming F; Flor B; Folkesson J; Foskett K; Frizelle FA; Funder J; Gallego MA; Garcia-Granero E; Garcia-Sabrido JL; Gargiulo M; Gava VG; Gentilini L; George ML; George V; Georgiou P; Ghosh A; Ghouti L; Gil-Moreno A; Giner F; Ginther N; Glover T; Goffredo P; Golda T; Gomez CM; Griffiths B; Gwenael F; Harris C; Harris DA; Hagemans JAW; Hanchanale V; Harji DP; Helbren C; Helewa RM; Hellawell G; Heriot AG; Hochman D; Hohenberger W; Holm T; Holmstroem A; Hompes R; Hornung B; Hurton S; Hyun E; Ito M; Iversen LH; Jenkins JT; Jourand K; Kaffenberger S; Kandaswamy GV; Kapur S; Kanemitsu Y; Kaufman M; Kazi M; Kelley SR; Keller DS; Kelly ME; Kersting S; Ketelaers SHJ; Khan MS; Khaw J; Kim H; Kim HJ; Kiran R; Koh CE; Kok NFM; Kokelaar R; Kontovounisios C; Kose F; Koutra M; Kraft M; Kristensen HO; Kumar S; Kusters M; Lago V; Lakkis Z; Lampe B; Langheinrich MC; Larach T; Larsen SG; Larson DW; Law WL; Laurberg S; Lee PJ; Limbert M; Loria A; Lydrup ML; Lyons A; Lynch AC; Mackintosh M; Mann C; Mantyh C; Mathis KL; Margues CFS; Martinez A; Martling A; Meijerink WJHJ; Merchea A; Merkel S; Mehta AM; Mcarthur DR; Mccormick JJ; Mcdermott FD; Mcgrath JS; Mcphee A; Maciel J; Malde S; Manfredelli S; Mikalauskas S; Modest D; Monson JRT; Morton JR; Mullaney TG; Navarro AS; Neeff H; Negoi I; Neto JWM; Nguyen B; Nielsen MB; Nieuwenhuijzen GAP; Nilsson PJ; Nordkamp S; O'Dwyer ST; Paarnio K; Palmer G; Pappou E; Park J; Patsouras D; Peacock A; Pellino G; Peterson AC; Pfeffer F; Piqeur F; Pinson J; Poggioli G; Proud D; Quinn M; Oliver A; Quyn A; Radwan RW; Rajendran N; Rao C; Rasheed S; Rasmussen PC; Rausa E; Regenbogen SE; Reims HM; Renehan A; Rintala J; Rocha R; Rochester M; Rohila J; Rothbarth J; Rottoli M; Roxburgh C; Rutten HJT; Safar B; Sagar PM; Sahai A; Saklani A; Sammour T; Sayyed R; Schizas AMP; Schwarzkopf E; Scripcariu D; Scripcariu V; Seifert G; Selvasekar C; Shaban M; Shaikh I; Shida D; Simpson A; Skeie-Jensen T; Smart NJ; Smart P; Smith JJ; Smith T; Solbakken AM; Solomon MJ; Sorensen MM; Spasojevic M; Steele SR; Steffens D; Stitzenberg K; Stocchi L; Stylianides NA; Swartling T; Sumrien H; Swartking T; Takala H; Tan EJ; Taylor C; Taylor D; Tejedor P; Tekin A; Tekkis PP; Teras J; Thanapal MR; Thaysen HV; Thorgersen E; Thurairaja R; Toh EL; Tsarkov P; Tolenaar J; Tsukada Y; Tsukamoto S; Tuech JJ; Turner G; Turner WH; Tuynman JB; Valente M; van Rees J; van Zoggel D; Vasquez-Jimenez W; Verhoef C; Vierimaa M; Vizzielli G; Voogt ELK; Uehara K; Wakeman C; Warrier S; Wasmuth HH; Weber K; Weiser MR; Westney OL; Wheeler JMD; Wild J; Wilson M; Wolthuis A; Yano H; Yip B; Yip J; Yoo RN; Zappa MA; Winter DC
  • Conference publication: DISEASES OF THE COLON & RECTUM. 2023;66(6):319-320
    Shahrivar M; Weibull CE; Glimelius B; Saraste D; Martling A; Buchli C; Nordenvall C
  • Conference publication: QUALITY OF LIFE RESEARCH. 2022;31:S79-S80
    Fuentes S; Radu C; Johansson H; Martling A; Glimelius B
  • Review: ACTA ONCOLOGICA. 2022;61(4):523-530
    Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
  • Editorial: BJS-BRITISH JOURNAL OF SURGERY. 2022;109(3):251-255
    Zaborowski AM; Abdile A; Adamina M; Aigner F; D'Allens L; Allmer C; Anula R; Andric M; Atallah S; Bach S; Bala M; Barussaud M; Bausys A; Beggs A; Bellolio F; Bennett M-R; Berdinskikh A; Bevan V; Biondo S; Bislenghi G; Bludau M; Brouwer N; Brown C; Bruns C; Buchanan DD; Buchwald P; Burger JWA; Burlov N; Campanelli M; Capdepont M; Carvello M; Chew H-H; Christoforidis D; Clark D; Climent M; Collinson R; Cologne KG; Contreras T; Croner R; Daniels I; Dapri G; Davies J; Delrio P; Denost Q; Deutsch M; Dias A; Drozdov E; Duek D; Dunlop M; Dziki A; Edmundson A; Efetov S; El-Hussuna A; Elliott B; Emile S; Espin-Basany E; Evans M; Faes S; Faiz O; Figueiredo N; Fleming F; Foppa C; Fowler G; Frasson M; Forgan T; Frizelle F; Gadaev S; Gellona J; Glyn T; Goran B; Greenwood E; Guren MG; Guillon S; Gutlic I; Hahnloser D; Hampel H; Hanly A; Hasegawa H; Iversen LH; Hill A; Hill J; Hoch J; Hompes R; Hurtado L; Iaquinandi F; Imbrasaite U; Islam R; Jafari MD; Kanemitsu Y; Karachun A; Karimuddin AA; Keller DS; Kelly J; Kennelly R; Khrykov G; Kocian P; Koh C; Kok N; Knight KA; Knol J; Kontovounisios C; Korner H; Krivokapic Z; Kronberger I; MaartenKroon H; Kryzauskas M; Kural S; Kusters M; Lakkis Z; Lankov T; Larson D; Lee K-Y; Lee SH; Lepisto A; Lieu C; Loi L; Lynch C; Maillou-Martinaud H; Maroli A; Martin ST; Martling A; Matzel KE; Mayol J; McDermott F; Meurette G; Millan M; Mitteregger M; Moiseenko A; Monson JRT; Morarasu S; Moritani K; Munini M; Nahas C; Nahas S; Negoi I; Novikova A; Ocares M; Okabayashi K; Olkina A; Onate-Ocana L; Otero J; Ozen C; Pace U; Sao Juliao GP; Panaiotti L; Panis Y; Papamichael D; Patel S; Peng S-L; Pera M; Perez RO; Petrov A; Pfeffer F; Phang TP; Poskus T; Pringle H; Proud D; Raguz I; Rama N; Rasheed S; Raval MJ; Rega D; Reissfelder C; Meneses JCR; Ris F; Riss S; Rodriguez-Zentner H; Roxburgh CS; Saklani A; Sammour T; Saraste D; Schneider M; Seishima R; Sekulic A; Seppala T; Sheahan K; Shlomina A; Sica G; Singnomklao T; Siragusa L; Smart N; Solis-Pena A; Spinelli A; Staiger RD; Stamos MJ; Steele S; Tan K-K; Tanis PJ; Tekkis P; Teklay B; Tengku S; Tsarkov P; Turina M; Ulrich A; Vailati BB; Van Harten M; Verhoef C; Warrier S; Wexner S; De Wilt H; Weinberg BA; Wells C; Wolthuis A; Xynos E; You N; Zakharenko A; Zeballos J; Zhou Y; Winter DC
  • Review: JAMA SURGERY. 2021;156(9):865-874
    Zaborowski AM; Abdile A; Adamina M; Aigner F; d'Allens L; Allmer C; Alvarez A; Anula R; Andric M; Atallah S; Bach S; Bala M; Barussaud M; Bausys A; Bebington B; Beggs A; Bellolio F; Bennett M-R; Berdinskikh A; Bevan V; Biondo S; Bislenghi G; Bludau M; Boutall A; Brouwer N; Brown C; Bruns C; Buchanan DD; Buchwald P; Burger JWA; Burlov N; Campanelli M; Capdepont M; Carvello M; Chew H-H; Christoforidis D; Clark D; Climent M; Cologne KG; Contreras T; Croner R; Daniels IR; Dapri G; Davies J; Delrio P; Denost Q; Deutsch M; Dias A; D'Hoore A; Drozdov E; Duek D; Dunlop M; Dziki A; Edmundson A; Efetov S; El-Hussuna A; Elliot B; Emile S; Espin E; Evans M; Faes S; Faiz O; Fleming F; Foppa C; Fowler G; Frasson M; Figueiredo N; Forgan T; Frizelle F; Gadaev S; Gellona J; Glyn T; Gong J; Goran B; Greenwood E; Guren MG; Guillon S; Gutlic I; Hahnloser D; Hampel H; Hanly A; Hasegawa H; Iversen LH; Hill A; Hill J; Hoch J; Hoffmeister M; Hompes R; Hurtado L; Iaquinandi F; Imbrasaite U; Islam R; Jafari MD; Kanemitsu Y; Karachun A; Karimuddin AA; Keller DS; Kelly J; Kennelly R; Khrykov G; Kocian P; Koh C; Kok N; Knight KA; Knol J; Kontovounisios C; Korner H; Krivokapic Z; Kronberger I; Kroon HM; Kryzauskas M; Kural S; Kusters M; Lakkis Z; Lankov T; Larson D; Lazar G; Lee K-Y; Lee SH; Lefevre JH; Lepisto A; Lieu C; Loi L; Lynch C; Maillou-Martinaud H; Maroli A; Martin S; Martling A; Matzel KE; Mayol J; McDermott F; Meurette G; Millan M; Mitteregger M; Moiseenko A; Monson JRT; Morarasu S; Moritani K; Moslein G; Munini M; Nahas C; Nahas S; Negoi I; Novikova A; Ocares M; Okabayashi K; Olkina A; Onate-Ocana L; Otero J; Ozen C; Pace U; Juliao GPS; Panaiotti L; Panis Y; Papamichael D; Park J; Patel S; Uriburu JCP; Pera M; Perez RO; Petrov A; Pfeffer F; Phang PT; Poskus T; Pringle H; Proud D; Raguz I; Rama N; Rasheed S; Raval MJ; Rega D; Reissfelder C; Meneses JCR; Ris F; Riss S; Rodriguez-Zentner H; Roxburgh CS; Saklani A; Salido AJ; Sammour T; Saraste D; Schneider M; Seishima R; Sekulic A; Seppala T; Sheahan K; Shine R; Shlomina A; Sica GS; Singnomklao T; Siragusa L; Smart N; Solis A; Spinelli A; Staiger RD; Stamos MJ; Steele S; Sunderland M; Tan K-K; Tanis PJ; Tekkis P; Teklay B; Tengku S; Jimenez-Toscano M; Tsarkov P; Turina M; Ulrich A; Vailati BB; van Harten M; Verhoef C; Warrier S; Wexner S; de Wilt H; Weinberg BA; Wells C; Wolthuis A; Xynos E; You N; Zakharenko A; Zeballos J; Winter DC
  • Editorial: BJS-BRITISH JOURNAL OF SURGERY. 2021;108(7):750-753
    de la Motte L; Custovic S; Tapper J; Arver S; Martling A; Buchli C
  • Study protocol: BJS OPEN. 2021;5(3):zrab029
    Voogt ELK; Nordkamp S; Aalbers AGJ; Buffart T; Creemers GJ; Marijnen CAM; Verhoef C; Havenga K; Holman FA; Kusters M; Marinelli AWKS; Melenhorst J; Aziz NA; Abecasis N; Abraham-Nordling M; Akiyoshi T; Alberda W; Albert M; Andric M; Angenete E; Antoniou A; Auer R; Austin KK; Aziz O; Baker RP; Bali M; Baseckas G; Bebington B; Bedford M; Bednarski BK; Beets GL; Beets-Tan RGH; Berbee M; Berg J; Berg PL; Beynon J; Biondo S; Bloemen JG; Boyle K; Bordeianou L; Bremers AB; Brunner M; Buchwald P; Bui A; Burgess A; Burling D; Burns E; Campain N; Carvalhal S; Castro L; Caycedo-Marulanda A; Ceha HM; Chan KKL; Chang GJ; Chang M; Chew MH; Chok AK; Chong P; Christensen HK; Clouston H; Codd M; Collins D; Colquhoun AJ; Corr A; Coscia M; Cosimelli M; Coyne PE; Crobach ASLP; Crolla RMPH; Croner RS; Damjanovic L; Daniels IR; Davies M; Davies RJ; Delaney CP; de Roos MAJ; de Wilt JHW; den Hartogh MD; Denost Q; Deseyne P; Deutsch C; Cappel RDVTN; de Vries M; Dieters M; Dietz D; Domingo S; Doukas M; Dozois EJ; Duff M; Eglinton T; Enrique-Navascues JM; Espin-Basany E; Evans MD; Eyjolfsdottir B; Fahy M; Fearnhead NS; Feshtali S; Flatmark K; Fleming F; Folkesson J; Frizelle FA; Frodin JE; Gallego MA; Garcia-Granero E; Garcia-Sabrido JL; Geboes K; Gentilini L; George ML; George V; Ghouti L; Giner F; Ginther N; Glyn T; Glynn R; Golda T; Grabsch HI; Griffiths B; Harris DA; Hagemans JA; Hanchanale V; Harji DP; Helewa RM; Helgason H; Hellawell G; Heriot AG; Heyman S; Hochman D; Hoff C; Hohenberger W; Holm T; Hompes R; Horsthuis K; Hospers G; Houwers J; Iversen H; Jenkins JT; Kaffenberger S; Kandaswamy GV; Kapur S; Kanemitsu Y; Kats-Ugurlu G; Kelley SR; Keller DS; Kelly ME; Keymeulen K; Khan MS; Kim H; Kim HJ; Koh CE; Kok NFM; Kokelaar R; Kontovounisios C; Kristensen HO; Kroon HM; Kumar S; Lago V; Lakkis Z; Lamberg T; Larsen SG; Larson DW; Law WL; Laurberg S; Lee PJ; Leseman-Hoogenboom MM; Limbert M; Lydrup ML; Lyons A; Lynch AC; Mantyh C; Mathis KL; Margues CFS; Martling A; Meijer OWM; Meijerink WJHJ; Merchea A; Merkel S; Mehta AM; McArthur DR; McDermott FD; McGrath JS; Malde S; Mirnezami A; Monson JR; Morton JR; Nederend J; Negoi I; Neto JWM; Ng JL; Nguyen B; Nielsen MB; Nieuwenhuijzen GAP; Nilsson PJ; Nilsson ML; Oei S; Oliver A; O'Dwyer ST; Oppedijk V; Palmer G; Pappou E; Park J; Patsouras D; Pellino G; Peterson AC; Peulen HMU; Poggioli G; Proud D; Quinn M; Quyn A; Rajendran N; Radwan RW; Rasheed S; Rasmussen PC; Rausa E; Regenbogen SE; Renehan A; Richir MC; Rocha R; Rochester M; Rohila J; Rothbarth J; Rottoli M; Roxburgh C; Rozema T; Safar B; Sagar PM; Sahai A; Saklani A; Sammour T; Sayyed R; Schizas AMP; Schwarzkopf E; Scripcariu V; Selvasekar C; Shaikh I; Shida D; Simpson A; Skeie-Jensen T; Slangen JJG; Smart NJ; Smart P; Smith JJ; Snaebjornsson P; Solbakken AM; Solomon MJ; Sorensen MM; Sorrentino L; Speetjens FM; Bilgen EJS; Steele SR; Steffens D; Stitzenberg K; Stocchi L; Stylianides NA; Swartling T; Sumrien H; Sutton PA; Swartking T; Tan EJ; Taylor C; Tekkis PP; Teras J; Terpstra V; Thurairaja R; Toh EL; Tsarkov P; Tsukada Y; Tsukamoto S; Tuech JJ; Turner WH; Tuynman JB; van Duyn EB; van Grevenstein WMU; van Grieken NCT; van Iersel L; van Lijnschoten G; van Meerten E; van Ramshorst GH; van Westreenen HL; van Zoggel D; Vasquez-Jimenez W; Velema LA; Verdaasdonk E; Verheul HMW; Versteeg KS; Vizzielli G; Uehara K; Wakeman C; Warrier S; Wasmuth HH; Weber K; Weiser MR; Wheeler JMD; Wijffels NAT; Wild J; Willems JMWE; Wilson M; Winter DC; Wolthuis A; Wumkes ML; Yano H; Yip B; Yip J; Yoo RN; Zappa MA; Zimmerman DDE; Rutten HJT; Burger JWA
  • Visa fler

Utvalda forskningsbidrag

  • Swedish Research Council
    1 januari 2023 - 31 december 2026
    The rapid development of technologies for molecular profiling paves the way for precision medicine approaches to match patients with effective treatment. Through the development of a coordinating support unit, we aim to provide access to SciLifeLab’s technology platforms to support academic and industry-initiated clinical trials. We will establish customized diagnostic packages jointly with clinical trials units across the country to strengthen our attractiveness as a clinical trial site and to ensure early access of patients to both innovative technologies and emerging treatments.Our goal is to identify mature technologies to be evaluated in observational studies and adopted in interventional biomarker-driven clinical trials. To build this capacity, connecting SciLifeLab national infrastructure to clinical practice, key developments supporting cross-platform data, sample and analysis flows with timelines and quality complying with the needs of clinical trials are needed. Our unit will unite services from current and emerging sequencing technologies, to proteome, metabolome, spatial biology techniques, and drug efficacy testing. Our competitive edge is the repertoire of technologies at SciLifeLab, which once combined provide a unique opportunity for clinical trials. With the ‘service packages’ we aim to make Sweden competitive as a trial site, catalyze academy-industry ecosystems and provide opportunities for early access to the latest diagnostic technologies and treatments.
  • Swedish Research Council
    1 januari 2014 - 31 december 2019

Forskningsbidrag

  • Skräddarsydd diagnostik, behandling och rehabilitering av kolorektalcancer patienter-randomiserade , observationella och epidemiologiska studier
    Cancer Society in Stockholm
    1 januari 2025 - 31 december 2027
  • Skräddarsydd diagnostik, behandling och rehabilitering av kolorektalcancer patienter-randomiserade , observationella och epidemiologiska studier
    ALF
    1 januari 2025 - 31 december 2027
  • Individualiserad diagnostik, behandling och rehabilitering av kolorektalcancer patienter - randomiserade, observationella och epidemiologiska studier
    Swedish Cancer Society
    1 januari 2024 - 31 december 2026
  • Swedish Colorectal Cancer Study Group
    Swedish Cancer Society
    1 januari 2024 - 31 december 2026
  • Swedish Research Council
    1 januari 2024 - 31 december 2026
    There is a large need for improved biomarkers and treatments in colorectal cancer (CRC). Immune surveillance plays a large part in the natural course and treatment sensitivity of CRC. Previous studies have largely neglected the regulatory roles of fibroblasts in immune regulation and have failed to consider regulatory processes in tumor draining lymph nodes.This project tests the hypothesis that well-informed  profiling of paired primary tumors and tumor draining lymph nodes can identify novel clinically relevant immune-regulatory processes with drug target and biomarker potential.The discovery-focused sub-study 1  use imaging mass cytometry for high-content in situ tissue profiling to identify novel fibroblast-regulated immune niches with preliminary outcome associations.The second sub-studyexpand findings with a multi-marker analysis of selected novel immune features in large clinically well-annotated colorectal cancer collections to explore their biomarker potential.Sub-study 3 use experimental co-culture studies for molecular characterization and CRISPR/Cas9-based target identification in fibroblast-regulated immune pathways suggested by the tissue profiling.Studies are developing large set of preliminary findings. Feasibility will be ensured by expertise of applicant on tumor microenvironment and tissue profiling, combined with colorectal cancer expertise of partner surgeon, oncologist, pathologist, and support from experts in tumor immunology and CRISPR/Cas9 screens.
  • Swedish Cancer Society
    1 januari 2024
    About 7,000 people in Sweden get colon and rectal cancer every year. Improved treatment has led to increased survival, but almost half of the patients still suffer from difficult-to-treat relapses with a high risk of death. In the case of widespread disease, there are treatments that prolong survival, but which only lead to a cure in a small percentage. Improved additional treatments and new biomarkers - with the aim of reducing the risk of relapse - would therefore be of the greatest value. The project includes epidemiological studies as well as studies of new treatments, preventive measures and development of new techniques and biomarkers for diagnostics, prognosis and treatment response for patients with colon and rectal cancer. New opportunities to analyze gene changes provide opportunities for prognostication and individualized treatment. For example, we are now conducting the first biomarker-based study of treatment with acetylsalicylic acid with the aim of reducing the risk of relapse. In tumor disease, tumor fragments containing DNA are released into the bloodstream, which can be a potentially very accurate and dynamic biomarker that is now being studied. Our research aims at more patient-specific care throughout the entire care chain in order to increase the chance of a cure and a reduction in suffering due to side effects. Furthermore, through improved additional treatments, we hope to reduce the risk of relapse. Through the creation of a national registry-based research platform including genetic data, we will enable almost limitless possibilities for future studies concerning relationships, signaling pathways and biomarkers. This will be an important step in the development of precision medicine with significant improvements in prevention, diagnosis and prognosis for patients with colon and rectal cancer.
  • Individualiserad mutidisciplinär diagnostik, behandling och rehabilitering av kolorektalcancer patienter-randomiserade , observationella och epidemiologiska studier
    ALF
    1 januari 2022 - 31 december 2024
  • Individualiserad mutidisciplinär diagnostik, behandling och rehabilitering av kolorektalcancer patienter-randomiserade , observationella och epidemiologiska studier
    Cancer Society in Stockholm
    1 januari 2022 - 31 december 2024
  • CITCCA-Circulating tumour DNA (ctDNA) as a prognostic and predictive biomarker in colorectal cancer
    Swedish Cancer Society
    1 januari 2021 - 31 december 2023
  • ARP (ALASCCA Research Platform)
    Private Donatino
    1 januari 2021 - 31 december 2023
  • Individualiserad diagnostik, behandling och rehabilitering av kolorektalcancer patienter - randomiserade, observationella och epidemiologiska studier
    Swedish Cancer Society
    1 januari 2021 - 31 december 2023
  • Swedish Cancer Society
    1 januari 2021
    Colon and rectal cancer affects approximately 6,800 people in Sweden annually. Treatment has improved, which has led to increased survival, but almost half of the patients still suffer from difficult-to-treat relapses with a high risk of death. In the case of widespread disease, there are treatments that prolong survival, but which only lead to a cure in a small percentage. Improved adjunctive treatments – with the aim of reducing the risk of relapse – would therefore be of the greatest value. We are towards the final phase of a study that studies the value of different radiation treatment regimens where the results show that a newly introduced regimen reduces the risk of side effects by about 40%. Furthermore, sexual function, hormones, bone breakdown and rehabilitation after radiotherapy are studied, which was previously sparsely studied. Acetylsalicylic acid has been shown to reduce the occurrence of polyps, reduce the risk of colon and rectal cancer and also reduce the risk of developing daughter tumors. We have now initiated the first biomarker-based study of treatment with acetylsalicylic acid in patients with colon and rectal cancer with the aim of reducing the risk of recurrence. Our clinical, close-to-patient research concerning various aspects of diagnosis, treatment and prognosis has led to improved treatment strategies, reduced relapses and improved survival. The research aims at more patient-specific care throughout the entire care chain in order to thereby increase the chances of a cure and a reduced suffering from side effects. Furthermore, through further improved additional treatments, we hope to reduce the risk of relapse. Through the creation of a national research platform, we will enable almost unlimited possibilities for future studies concerning connections, signaling pathways and biomarkers.
  • CAST- Active monitoring of cancer as an alternative to surgery
    EU Project
    1 januari 2020 - 31 december 2023
  • ALASCCA-Adjuvant low dose Aspirin in patients with colorectal cancer and PIK3CA mutation
    Private Donation
    1 januari 2020 - 31 december 2022
  • Swedish Research Council
    1 januari 2020 - 31 december 2020
  • CITCCA-Circulating tumour DNA (ctDNA) as a prognostic and predictive biomarker in colorectal cancer
    Private Donation
    1 januari 2019 - 31 december 2020
  • Multidisciplinary treatment and assessment of rectal cancer
    Swedish Cancer Society
    1 januari 2018 - 31 december 2020
  • Improved patient-specific investigation, treatment and rehabilitation of patients with rectal cancer
    Swedish Cancer Society
    1 januari 2018
    Thick and rectal cancer annually affects about 6,000 people. The treatment is essentially surgical. In recent years, treatment has improved, which has led to increased survival in the disease, but still nearly half of the patients suffer from difficult-to-treat relapses. In spite of a localized tumor, 20-40% of patients will develop remote proliferation at high risk of death. In spreading disease there are new treatments that prolong survival, but only in a small proportion of patients leads to cure. Improved add-on treatments - in order to reduce the risk of relapse - would therefore be of greatest value. We are towards the final phase of a randomized multicentre study that studies the value of different radiation treatment regimens where the results show that a newly introduced regimen can reduce the risk of side effects by about 40% while maintaining good oncological results. Furthermore, sexual function and hormones are studied after radiation therapy, which has been sparingly studied previously. Treatment with acetylsalicylic acid (ASA) has shown to reduce the incidence of polyps, reduce the risk of colon and rectal cancer and also reduce the risk of developing daughter tumors. We have now initiated the first biomarker-based study of treatment with ASA in patients with colorectal cancer. Our clinical, patient-related research on various aspects of diagnosis, treatment and prognosis in rectal cancer has resulted in altered treatment strategies and reduced local recurrence rates and improved survival. The research program aims at a more patient-specific cancer incident throughout the care chain from diagnostics to rehabilitation, thereby increasing the chances of cure and a reduced suffering of side effects. Furthermore, we hope that further improved supplementary treatments will reduce the risk of relapse. Our studies are all well applicable in clinical practice and will immediately benefit the patients.
  • Improved patient-specific investigation, treatment and rehabilitation of patients with rectal cancer
    Swedish Cancer Society
    1 januari 2017
    Thick and rectal cancer annually affects about 6,000 people. The treatment is essentially surgical. In recent years, treatment has improved, which has led to increased survival in the disease, but still nearly half of the patients suffer from difficult-to-treat relapses. In spite of a localized tumor, 20-40% of patients will develop remote proliferation at high risk of death. In spreading disease there are new treatments that prolong survival, but only in a small proportion of patients leads to cure. Improved add-on treatments - in order to reduce the risk of relapse - would therefore be of greatest value. We are towards the final phase of a randomized multicentre study that studies the value of different radiation treatment regimens where the results show that a newly introduced regimen can reduce the risk of side effects by about 40% while maintaining good oncological results. Furthermore, sexual function and hormones are studied after radiation therapy, which has been sparingly studied previously. Treatment with acetylsalicylic acid (ASA) has shown to reduce the incidence of polyps, reduce the risk of colon and rectal cancer and also reduce the risk of developing daughter tumors. We have now initiated the first biomarker-based study of treatment with ASA in patients with colorectal cancer. Our clinical, patient-related research on various aspects of diagnosis, treatment and prognosis in rectal cancer has resulted in altered treatment strategies and reduced local recurrence rates and improved survival. The research program aims at a more patient-specific cancer incident throughout the care chain from diagnostics to rehabilitation, thereby increasing the chances of cure and a reduced suffering of side effects. Furthermore, we hope that further improved supplementary treatments will reduce the risk of relapse. Our studies are all well applicable in clinical practice and will immediately benefit the patients.
  • Sexual function, well-being and hormone levels in women and men with rectal cancer: the importance of early intervention and sexual rehabilitation
    Swedish Cancer Society
    1 januari 2016
    Intestinal cancer is the seventh most common form of cancer and is mainly treated with surgery, sometimes in combination with radiation therapy. However, the treatment may cause side effects. Sexual dysfunction is well described in men, but less in women. The cause may be the surgical trauma, lack of intestinal function, urinary incontinence, stoma and bodily changes. In the radiation treatment, ovaries and testicles are exposed to radiation, which can lead to premature menopause, infertility, fragile mucous membranes and intercourse pain, and possibly a hormone deficiency. In men, decreased testosterone levels are seen, in women this has not previously been studied. We intend to study how radiation therapy and pelvic surgery in women and men with rectal cancer affect hormone levels, sexual function and well-being. In men, the influence on sperm production will also be studied, which has also been sparingly studied previously. Based on the results of the previous studies within the project, we have initiated a new study that studies the value of early intervention with the addition of PDE-5 inhibitors in low dose and testosterone substitution on sexual function after treatment of rectal cancer which has not previously been studied. In recent decades, treatment and prognosis in rectal cancer has improved significantly and more and more people survive the disease. It is thus becoming increasingly important to study the quality of life after the treatment has been completed. The objectives of the project are to increase knowledge of sexual function, quality of life and hormone levels after radiotherapy and surgery in women and men with rectal cancer and to improve the care of this large patient group regarding psychosexual prevention, information, rehabilitation and intervention.
  • Visa fler

Anställningar

  • Professor/Överläkare, Kirurgi, Molekylär medicin och kirurgi, Karolinska Institutet, 2014-
  • Överläkare, Karolinska Universitetssjukhuset, Solna, ME Bäckencancer, Kolorektalsektionen, 2010-
  • Forskargruppsledare, Forskargruppen för kolorektal kirurgi, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2008-
  • Scientific Director Life Science, Karolinska Institutet, 2024-2024
  • Ordförande Task Force Precision Medicine Karolinska Institutet - Region Stockholm, Karolinska Institutet - Region Stockholm, 2020-2023
  • Dekan KI Nord, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2019-2023
  • Biträdande chef för Gastrocentrum, Gastrocentrum, Karolinska Universitetssjukhuset, 2010-2013
  • Verksamhetschef, Kirurgkliniken, Kirurgkliniken, Karolinska Universitetssjukhuset, 2006-2008

Examina och utbildning

  • Docent, Kirurgi, Karolinska Institutet, 2009
  • MEDICINE DOKTORSEXAMEN, INST F KIRURGISK VETENSKAP (K3), Karolinska Institutet, 2003
  • Läkarexamen, Karolinska Institutet, 1994

Uppdrag

  • Forskargruppsledare, CITCCA - CIrculating Tumour DNA in Colorectal CAncer, Karolinska Institutet, 2020-
  • Forskargruppsledare, EROS - EaRly interventiOn and Sexual rehabilitation, Karolinska Institutet, 2018-
  • Forskargruppsledare, ALASCCA-trial
  • Adjuvant Low dose ASpirin in patients with Colorectal CAncer, Karolinska Institutet, 2016-
  • Forskargruppsledare, Stockholm III Trial, Karolinska Institutet, 2007-2013

Priser och utmärkelser

  • Best papers award, ESCP mötet2025, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2025
  • Honorary Fellow of American College of Surgeons (FACS), American College of Surgeons, 2023
  • Honorary Fellow of European Society of Coloproctology (FESCP), European Society of Coloproctology, 2023
  • Honorary Fellow of Royal College of Surgeons of England (FRCS), Royal College of Surgeons of England, 2022
  • Member, BJS Award Committee, 2022
  • Årets Cancerforskare, Cancerfonden, Swedish Cancer Society, 2021
  • Honorary Fellowship, American Society of Colon and Rectal Surgeons, 2020
  • Honorary Fellow of American Society of Colon and Rectal Surgeons (FASCRS), American Society of Colon and Rectal Surgeons, 2020
  • Member, International Surgical Group (ISG), 2020
  • Med dr Axel Hirsch Pris, Karolinska Institutet, Karolinska Institutet, 2019
  • Tarmcancerpriset, ILCO, Tarm- uro- och stomiförbundet, ILCO, Tarm- uro- och stomiförbundet, 2019
  • Hilda och Alfred Erikssons pris, Kungliga Vetenskapsakademin, Royal Swedish Academy of Sciences, 2018
  • Marc-Claude Marti Lecture, Villars, Switzerland, 2017
  • Årets Lennanderföreläsare, Svenska Läkaresällskapet, Swedish Society of Medicine, 2016
  • Six best papers award, ESCP meeting, 2016
  • The Edward Wilson Lecture, Sydney, Australia, 2015
  • Six best papers award, ESCP meeting, 2015
  • Svensk Kirurgisk Förenings Stora Forskarpris, Swedish Surgical Society, 2013
  • Six best papers award, ESCP meeting, 2012
  • Young Investigator Award, 6 years of salary stipend for postdoctoral researchers in Sweden working on cancer research, Cancerfonden, 2008
  • Six best papers award, ESCP meeting, 2008
  • Young Promising Researcher, Karolinska Institutet, 2003

Handledning

  • Handledning till doktorsexamen

    • Louise de la Motte, Sequele after multimodal treatment of rectal cancer, 2026
    • Sofieke Temmink, Organ preservation in rectal cancer: Implementation and quality assurance, 2025
    • Mehrnoosh Shahrivar, Aspirin use, genetic profile and prognosis in patients with colorectal cancer, 2025
    • Rebecka Bergström, 2024-
    • Petri Rantanen, On the clinical evaluation of morhology related and other risk factors in colorectal cancer patients, 2024
    • Ida Hed Myrberg, 2023-
    • Sol Erika Boman, 2023-
    • Cecilia Merk, 2022-
    • Annika Svanström Röjvall, Adverse effects of treatment for rectal cancer- Sexual function, hormones, and bone health, 2022
    • Huang Linglong, 2021-
    • John Tapper, Hormones, Muscles and Oncological Outcome in men with rectal cancer, 2019
    • Johan Erlandsson, Preoperative radiotherapy in rectal cancer - Aspects on fractionation and timing to surgery, 2019
    • Emeli Pontén, Epidemiological and genetic studies of childhood cancer etiology, 2018-
    • Richard Bernhoff, Coloncancer- aspects on surgical treatment and Complete Mesocolic Excision, 2018
    • Emelie Ponten, 2017-
    • Anders Hansson Elliot, On preoperative treatment selection and magnetic resonance imaging in rectal cancer, 2017
    • Karin Westberg, Locally recurrent rectal cancer-aspects on management, surgery and outcome, 2017
    • Stina Fuentes, Adverse effects and quality of life after radiotherapy and surgery for rectal cancer - a randomized controlled trial enriched with register data, 2016-
    • Patrik Lundström, 2015-
    • Christian Buchli, Rectal cancer : aspects on radiotherapy, androgens and body composition, 2015
    • Deborah Saraste, Early rectal cancer and screening for colorectal cancer, 2015
    • Claes Anderin, Low rectal cancer : aspects of surgical techniques and treatment results, 2012
    • David Pettersson, Preoperative radiotherapy in rectal cancer – aspects of different regimens, 2012
    • Josefin Segelman, Colorectal Cancer – Aspects of multidisciplinary treatment, metastatic disease and sexual function, 2012
    • Gabriella Jansson Palmer, Locally advanced rectal cancer : aspects on management, outcome and quality of life, 2009
    • Michael Torkzad, Magnetic resonance imaging of rectum : diagnostic and therapy related aspects, 2006

Uppdrag i kommitté

  • Medlem, Steering committee Centre for AI Innovation, Karolinska Institutet, 2025-
  • Medlem, Forskningrådet KI/Region Stockholm, 2025-
  • Medlem, Styrgrupp, Swedish Quantum Life Science Center, 2023-2025
  • Medlem, Steering committee, Genomic Medicine Sweden (GMS), 2023-2024
  • Medlem, Styrgrupp, Clinicum, Karolinska Institutet, 2021-
  • Medlem, Board of Trustees, European Society of Coloproctology (ESCP), 2021-
  • Medlem, Styrelse, Cancerfonden, 2020-2023
  • Ordförande, Task-force Precision Medicine, Karolinska Institutet, 2020-2023
  • Medlem, Board, Forska Sverige, 2020-
  • Medlem, Board of Directors, Karolinska Cancer Comprehensive Center (KCCC), 2020-2023
  • Medlem, Board, KI/Region Stockholm, 2019-2023
  • Medlem, Board, Bactiguard (Sweden), 2019-
  • Medlem, Board, S:t Eriks Ögonsjukhus, 2019-
  • Ordförande, Stiftelsen Konung Gustaf V:s Jubileumsfond, 2019-2024
  • Medlem, Faculty Board, Karolinska Institutet, 2019-2023
  • Medlem, Board of Directors, Centrum for Innovative Medicine (CIMED), 2018-2023
  • Medlem, Board of Research, Karolinska Institutet, 2015-2018
  • Ordförande, Program/Scientific Committee, European Society of Coloproctology (ESCP), 2015-2018
  • Ordförande, Swedish Colorectal Cancer Study Group, 2015-
  • Ordförande, Bengt Ihre Research Fellowship, 2012-2016
  • Medlem, Scientific Committee and Research Council, Swedish Cancer Society, 2012-2017
  • Medlem, Scientific committee, Swedish Cancer Society, 2012-2018
  • Medlem, United European Gastroenterology Federation Scientific Committee, 2010-2012
  • Ordförande, Stockholm Colorectal Cancer Study Group, 2008-
  • Annat, Advisor, ad hoc committee for development of National Centers of Excellence for the Treatment of Rectal Cancer, American Society of Colon and Rectal Surgeons, 2008-2008
  • Medlem, Steering Committee, Swedish Colorectal Cancer Registry, 2008-2019
  • Medlem, Swedish Colorectal Surgery Society, 2004-2006

Redaktör för vetenskaplig tidskrift

  • British Journal of Surgery, Medlem i redaktionskommittén, 2016-2025
  • European Journal of Surgical Oncology, Biträdande redaktör, 2014-2017
  • Colorectal Disease, Biträdande redaktör, 2014-2019

Nyheter från KI

Kalenderhändelser från KI